Coronary Atheroscleroses
Conditions
Keywords
Chronic total occlusion, Percutaneous coronary intervention, Major adverse cardiovascular events
Brief summary
Coronary chronic total occlusions (CTOs) are considered to increase the risk of adverse clinical outcomes. The purpose of this study was to evaluate whether long-term clinical outcomes could be improved by successful percutaneous coronary intervention (PCI) over optimal medical therapy (OMT) in CTO patients.
Detailed description
patients with CTO lesions undergoing PCI at the First Affiliated Hospital of Nanjing Medical University from January 2011 to December 2017 were enrolled. After someone were excluded due to CABG surgery, patients who met the enrollment criteria were divided into successful CTO-PCI group and CTO-OMT group based on the treatment received. The study primary endpoint was major adverse cardiac cerebrovascular events (MACCE), including cardiac death, recurrent myocardial infarction, unplanned revascularization, and stroke. The secondary endpoint was all-cause death.
Interventions
PROCEDUREPCI
successful percutaneous coronary intervention (PCI) in Coronary chronic total occlusions (CTOs) patients
DRUGOMT
optimal medical therapy (OMT) in CTO patients, such as aspirin 1td, ACEI/ARB 1td, β blocker 1td, statin 1td.
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* patients with at least one coronary CTO lesion at our hospital in between January 2011 and December 2017
Exclusion criteria
* (1) patients with ST-segment elevation myocardial infarction (STEMI) * (2)a history of coronary artery bypass grafting (CABG) * (3) cardiogenic shock * (4) malignant tumor. Patients were referred for PCI based on CTO-related symptoms or evidence of viability, or corresponding ischemia in the area of the CTO artery.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| major adverse cardiac cerebrovascular events (MACCE) | January 2011 to December 2023 | including cardiac death, recurrent myocardial infarction, unplanned revascularization, and stroke. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| all-cause death | January 2011 to December 2023 | all-cause death |
Countries
China
Contacts
Primary ContactMei Wang
Backup ContactLei Jiang
Outcome results
None listed